Scopio Labs, renowned for its expertise in digital cell morphology, has achieved a significant milestone with the FDA granting De Novo clearance for its Full-Field Bone Marrow Aspirate (FF-BMA) Application.
This clearance from the FDA signifies a groundbreaking moment, establishing a new regulatory category for digital bone marrow aspirate analysis software in the United States.
Importance of Bone Marrow Analysis in Blood Disorder Diagnosis
Bone marrow analysis, particularly through microscopic examination of samples (known as bone marrow cytology), remains indispensable in diagnosing a broad spectrum of blood disorders. Hematologic malignancies, a significant contributor to the global cancer burden, constitute approximately 10% of all diagnosed cancers in the US. Bone marrow aspirates (BMAs) are instrumental in identifying these malignancies and other blood-related conditions.
Addressing Traditional Challenges with a Digital Solution
Yet, the conventional manual analysis of BMAs presents challenges such as labour intensiveness, time consumption, and dependence on highly skilled hematopathologists, which can hinder efficiency and accessibility. Scopio’s FF-BMA Application revolutionises this process by introducing a fully digital workflow seamlessly integrated with their X100 and X100HT platforms.
Advantages for Healthcare Professionals and Patients
This groundbreaking solution offers:
High-resolution Full-Field imaging: Offering a comprehensive view of the sample to facilitate detailed analysis.
AI-powered decision support system (DSS): Aids in tasks like cell detection and categorization, enhancing efficiency and accuracy for healthcare professionals.
Click here to read the original news story.